{
  "pmcid": "PMC8973308",
  "pmid": "35431360",
  "title": "Susceptibility to thiopurine toxicity by TPMT and NUDT15 variants in Colombian children with acute lymphoblastic leukemia",
  "overall_score": 0.6876771134711062,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.8208217448309848,
      "total_samples": 2,
      "ground_truth_annotations": {
        "count": 2,
        "matched_count": 2,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8215034039396989,
            "annotation": {
              "Variant/Haplotypes": "rs116855232",
              "Gene": "NUDT15",
              "PMID": 35431360,
              "Phenotype Category": "Dosage",
              "Significance": "no",
              "Alleles": "CT",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "Drug(s)": "mercaptopurine"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs116855232",
                "prediction": "rs116855232",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "NUDT15",
                "prediction": "NUDT15",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 35431360,
                "prediction": 35431360,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "toxicity",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "no",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT",
                "prediction": "C/T",
                "score": 0.8984260559082031,
                "match_status": "partial_match"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric",
                "score": 1.0,
                "match_status": "match"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "toxicity outcomes of",
                "score": 0.8452063202857971,
                "match_status": "partial_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with",
                "score": 1.0,
                "match_status": "match"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Acute lymphoblastic leukemia",
                "prediction": "Disease:Acute Lymphoblastic Leukemia",
                "score": 0.9599190950393677,
                "match_status": "match"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C/C",
                "score": 0.9050132036209106,
                "match_status": "partial_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "6-mercaptopurine",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8201400857222708,
            "annotation": {
              "Variant/Haplotypes": "rs1800460",
              "Gene": "TPMT",
              "PMID": 35431360,
              "Phenotype Category": "Dosage",
              "Significance": "no",
              "Alleles": "CT",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "Drug(s)": "mercaptopurine"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1800460",
                "prediction": "rs1800460",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "TPMT",
                "prediction": "TPMT",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 35431360,
                "prediction": 35431360,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "toxicity",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "no",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT",
                "prediction": "C/G",
                "score": 0.8725230097770691,
                "match_status": "partial_match"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric",
                "score": 1.0,
                "match_status": "match"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "toxicity outcomes of",
                "score": 0.8452063202857971,
                "match_status": "partial_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with",
                "score": 1.0,
                "match_status": "match"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Acute lymphoblastic leukemia",
                "prediction": "Disease:Acute Lymphoblastic Leukemia",
                "score": 0.9599190950393677,
                "match_status": "match"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C/C",
                "score": 0.9050132036209106,
                "match_status": "partial_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "6-mercaptopurine",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 12,
        "items": [
          {
            "variant": "rs116855232",
            "gene": "NUDT15",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "rs116855232",
              "Gene": "NUDT15",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "For NUDT15 rs116855232, 2 of 4 C/T heterozygous patients required 6-MP dose reduction during 6\u2011month maintenance follow-up, but chi-square tests for association with 6-MP dose reduction or interruption showed no statistically significant association (Table 4).",
              "Sentence": "Genotype C/T is not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to genotype C/C.",
              "Alleles": "C/T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "[Table 4] summarizes the results of the bivariate analyzes in which the correlation between the genetic variants of the SNPs of interest in NUDT15 and TPMT and the side effects of interest. No association was found between the outcomes of interest and the genetic variant of NUDT15 or any TPMT polymorphisms evaluated individually.",
                "Although no statistically significant associations were identified, two of the four patients heterozygous for NUDT15 required a decrease in 6-MP during the follow-up period."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs116855232",
                "variant_id": "PA166154759",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1800462",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs1800462",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Among 68 genotyped patients, 4 were rs1800462 C/T heterozygotes. Two of the four heterozygous patients presented febrile neutropenia and required discontinuation of 6-MP during the first six months, but overall, no statistically significant association was found between rs1800462 and myelotoxicity, liver toxicity, febrile neutropenia, relapse, or death (Table 4).",
              "Sentence": "Genotype C/T is not associated with increased toxicity outcomes of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to genotype C/C.",
              "Alleles": "C/T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity outcomes of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.\"",
                "\"Table 4 Caption: Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the polymorphisms studied and the outcomes of interest.\"",
                "\"Concerning the genetic variants of TPMT, for rs1800462, two of the four heterozygous patients presented febrile neutropenia, and the same patients also required discontinuation 6-MP during the first six months of maintenance therapy.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1800462",
                "variant_id": "PA166156993",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1800462",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "rs1800462",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "No statistically significant association was found between TPMT rs1800462 genotype and 6-MP dose reduction or interruption (Table 4). In the C/T group, 2/4 patients had 6-MP reduction and all 4 had 6-MP interruption, but chi-square tests were non-significant.",
              "Sentence": "Genotype C/T is not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to genotype C/C.",
              "Alleles": "C/T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Table 4 Caption: Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the polymorphisms studied and the outcomes of interest.",
                "[Table 4] summarizes the results of the bivariate analyzes in which the correlation between the genetic variants of the SNPs of interest in *NUDT15* and *TPMT* and the side effects of interest. No association was found between the outcomes of interest and the genetic variant of *NUDT15* or any *TPMT* polymorphisms evaluated individually.",
                "No statistically significant association was identified between the genetic variants and the outcomes of interest."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1800462",
                "variant_id": "PA166156993",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1800460",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "rs1800460",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "Of six rs1800460 C/G heterozygous patients, three required 6-MP dose decrease; two of these were also heterozygous for rs1142345. However, bivariate analysis showed no statistically significant association between rs1800460 and 6-MP dose reduction or interruption (Table 4).",
              "Sentence": "Genotype C/G is not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to genotype C/C.",
              "Alleles": "C/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.\"",
                "\"[Table 4](#t5) summarizes the results of the bivariate analyzes in which the correlation between the genetic variants of the SNPs of interest in NUDT15 and TPMT and the side effects of interest. No association was found between the outcomes of interest and the genetic variant of NUDT15 or any TPMT polymorphisms evaluated individually.\"",
                "\"In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1800460",
                "variant_id": "PA166156992",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1142345",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "rs1142345",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 42 patients successfully typed for rs1142345, 4 were heterozygous C/T. No statistically significant association was found between rs1142345 genotype and myelotoxicity, liver toxicity, febrile neutropenia, relapse, or death (Table 4).",
              "Sentence": "Genotype C/T is not associated with increased toxicity outcomes of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to genotype C/C.",
              "Alleles": "C/T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity outcomes of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "[Table 4 Caption:] Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the polymorphisms studied and the outcomes of interest.",
                "Although no statistically significant associations were identified, two of the four patients heterozygous for NUDT15 required a decrease in 6-MP during the follow-up period. Concerning the genetic variants of TPMT, for rs1800462, two of the four heterozygous patients presented febrile neutropenia, and the same patients also required discontinuation 6-MP during the first six months of maintenance therapy. In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1142345",
                "variant_id": "PA166156978",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1142345",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "rs1142345",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "Two rs1142345 C/T heterozygous patients overlapped with rs1800460 heterozygotes who required 6-MP dose reduction; nevertheless, overall chi-square tests showed no statistically significant association between rs1142345 and 6-MP dose reduction or interruption (Table 4).",
              "Sentence": "Genotype C/T is not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to genotype C/C.",
              "Alleles": "C/T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cGenetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.\u201d",
                "\u201c[Table 4] summarizes the results of the bivariate analyzes in which the correlation between the genetic variants of the SNPs of interest in NUDT15 and TPMT and the side effects of interest. No association was found between the outcomes of interest and the genetic variant of NUDT15 or any TPMT polymorphisms evaluated individually.\u201d",
                "\u201cAlthough no statistically significant associations were identified, two of the four patients heterozygous for NUDT15 required a decrease in 6-MP during the follow-up period. Concerning the genetic variants of TPMT, for rs1800462, two of the four heterozygous patients presented febrile neutropenia, and the same patients also required discontinuation 6-MP during the first six months of maintenance therapy. In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1142345",
                "variant_id": "PA166156978",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "TPMT*1",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "TPMT*1",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 42 patients with complete TPMT typing (rs1800462, rs1800460, rs1142345), haplotypes were *1 (n=78), *2 (n=2), *3A (n=4); diplotypes: *1/*1 (n=36), *1/*2 (n=2), *1/*3A (n=4). Comparison of *1/*1 versus *1/another (*1/*2 or *1/*3A) showed no statistically significant association with myelotoxicity, liver toxicity, neutropenia, relapse, or death (Supplementary Table 1S; all p\u22650.557).",
              "Sentence": "TPMT diplotypes *1/*2 + *1/*3A are not associated with increased toxicity outcomes of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to diplotype *1/*1.",
              "Alleles": "*1/*2 + *1/*3A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity outcomes of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Similar analyses were carried out about the typing of *TPMT*, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association ([supplementary table 1S](#t7)).\"",
                "\"Table 1S. Association analysis between TPMT diplotypes and outcomes. ... Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.\"",
                "\"No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*1, TPMT*2, TPMT*3A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*2",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "TPMT*2",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 42 patients with complete TPMT typing (rs1800462, rs1800460, rs1142345), haplotypes were *1 (n=78), *2 (n=2), *3A (n=4); diplotypes: *1/*1 (n=36), *1/*2 (n=2), *1/*3A (n=4). Comparison of *1/*1 versus *1/another (*1/*2 or *1/*3A) showed no statistically significant association with myelotoxicity, liver toxicity, neutropenia, relapse, or death (Supplementary Table 1S; all p\u22650.557).",
              "Sentence": "TPMT diplotypes *1/*2 + *1/*3A are not associated with increased toxicity outcomes of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to diplotype *1/*1.",
              "Alleles": "*1/*2 + *1/*3A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity outcomes of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Similar analyses were carried out about the typing of *TPMT*, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association ([supplementary table 1S](#t7)).\"",
                "\"Table 1S. Association analysis between TPMT diplotypes and outcomes. ... Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.\"",
                "\"No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*1, TPMT*2, TPMT*3A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*3A",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "TPMT*3A",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 42 patients with complete TPMT typing (rs1800462, rs1800460, rs1142345), haplotypes were *1 (n=78), *2 (n=2), *3A (n=4); diplotypes: *1/*1 (n=36), *1/*2 (n=2), *1/*3A (n=4). Comparison of *1/*1 versus *1/another (*1/*2 or *1/*3A) showed no statistically significant association with myelotoxicity, liver toxicity, neutropenia, relapse, or death (Supplementary Table 1S; all p\u22650.557).",
              "Sentence": "TPMT diplotypes *1/*2 + *1/*3A are not associated with increased toxicity outcomes of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to diplotype *1/*1.",
              "Alleles": "*1/*2 + *1/*3A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity outcomes of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Similar analyses were carried out about the typing of *TPMT*, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association ([supplementary table 1S](#t7)).\"",
                "\"Table 1S. Association analysis between TPMT diplotypes and outcomes. ... Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.\"",
                "\"No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*1, TPMT*2, TPMT*3A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*1",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "TPMT*1",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "TPMT diplotypes *1/*1 (n=36) versus *1/another (*1/*2 or *1/*3A, n=6) showed no statistically significant association with 6-MP dose reduction (p=0.616) or 6-MP interruption (p=0.308) (Supplementary Table 1S).",
              "Sentence": "TPMT diplotypes *1/*2 + *1/*3A are not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to diplotype *1/*1.",
              "Alleles": "*1/*2 + *1/*3A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Similar analyses were carried out about the typing of *TPMT*, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association ([supplementary table 1S](#t7)).\"",
                "\"Table 1S. Association analysis between TPMT diplotypes and outcomes. ... Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.\"",
                "\"2) What were the most relevant results of the study? |\n| No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP). |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*1, TPMT*2, TPMT*3A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*2",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "TPMT*2",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "TPMT diplotypes *1/*1 (n=36) versus *1/another (*1/*2 or *1/*3A, n=6) showed no statistically significant association with 6-MP dose reduction (p=0.616) or 6-MP interruption (p=0.308) (Supplementary Table 1S).",
              "Sentence": "TPMT diplotypes *1/*2 + *1/*3A are not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to diplotype *1/*1.",
              "Alleles": "*1/*2 + *1/*3A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Similar analyses were carried out about the typing of *TPMT*, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association ([supplementary table 1S](#t7)).\"",
                "\"Table 1S. Association analysis between TPMT diplotypes and outcomes. ... Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.\"",
                "\"2) What were the most relevant results of the study? |\n| No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP). |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*1, TPMT*2, TPMT*3A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*3A",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "TPMT*3A",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "TPMT diplotypes *1/*1 (n=36) versus *1/another (*1/*2 or *1/*3A, n=6) showed no statistically significant association with 6-MP dose reduction (p=0.616) or 6-MP interruption (p=0.308) (Supplementary Table 1S).",
              "Sentence": "TPMT diplotypes *1/*2 + *1/*3A are not associated with increased dose reduction or interruption of 6-mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia as compared to diplotype *1/*1.",
              "Alleles": "*1/*2 + *1/*3A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose reduction or interruption of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Similar analyses were carried out about the typing of *TPMT*, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association ([supplementary table 1S](#t7)).\"",
                "\"Table 1S. Association analysis between TPMT diplotypes and outcomes. ... Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.\"",
                "\"2) What were the most relevant results of the study? |\n| No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP). |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*1, TPMT*2, TPMT*3A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.6045082236329714,
      "total_samples": 1,
      "ground_truth_annotations": {
        "count": 1,
        "matched_count": 1,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.682051008939743,
            "annotation": {
              "Variant/Haplotypes": "rs1800462",
              "Gene": "TPMT",
              "Drug(s)": "mercaptopurine",
              "Phenotype Category": "Toxicity",
              "Alleles": "CG",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Febrile neutropenia, Side Effect:Discontinuation",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1800462",
                "prediction": "rs1800462",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "TPMT",
                "prediction": "TPMT",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "6-mercaptopurine",
                "score": 0.9638165831565857,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CG",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Febrile neutropenia, Side Effect:Discontinuation",
                "prediction": "Side Effect:Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death",
                "score": 0.9516803026199341,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C/C",
                "score": 0.9050132036209106,
                "match_status": "partial_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 3,
        "items": [
          {
            "variant": "rs116855232",
            "gene": "NUDT15",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "rs116855232",
              "Gene": "NUDT15",
              "Drug(s)": "6-mercaptopurine",
              "PMID": "35431360",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 68 Colombian pediatric ALL patients on 6-MP maintenance, NUDT15 rs116855232 C/T heterozygotes (4/68) showed no statistically significant association with 6-MP dose reduction, interruption, neutropenia, liver toxicity, relapse, or death compared with C/C. Two of four heterozygotes required 6-MP dose reduction.",
              "Sentence": "rs116855232 is not associated with increased risk of Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death when treated with 6-mercaptopurine in children with Disease:Acute lymphoblastic leukemia.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": "35431360",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "\"Seventy pediatric patients were included in the study. Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.\"",
                "\"The outcomes of interest were side effects as myelotoxicity and liver toxicity and the dose reduction or interruption of 6-MP. As an exploratory analysis, we evaluated other outcomes as febrile neutropenia, relapse and deaths.\"",
                "\"Although no statistically significant associations were identified, two of the four patients heterozygous for NUDT15 required a decrease in 6-MP during the follow-up period.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs116855232",
                "variant_id": "PA166154759",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1800460",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs1800460",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": "35431360",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 68 Colombian pediatric ALL patients on 6-MP maintenance, TPMT rs1800460 C/G heterozygotes (6/68) showed no statistically significant association with 6-mercaptopurine dose reduction, interruption, neutropenia, relapse, death, or laboratory markers versus C/C. Three of six heterozygous patients required 6-MP dose decrease; two of these were also heterozygous for rs1142345.",
              "Sentence": "rs1800460 is not associated with increased risk of Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death when treated with 6-mercaptopurine in children with Disease:Acute lymphoblastic leukemia.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": "35431360",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "[Table 4] summarizes the results of the bivariate analyzes in which the correlation between the genetic variants of the SNPs of interest in NUDT15 and TPMT and the side effects of interest. No association was found between the outcomes of interest and the genetic variant of NUDT15 or any TPMT polymorphisms evaluated individually.",
                "In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345. Additionally, differences in the median for the lab values taken in the first 6 months of maintenance treatment were evaluated: aminotransferases, total bilirubin, leukocytes, and differential cell counts; based on genetic variants, no statistically significant differences were found ([Supplementary table 2S])."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1800460",
                "variant_id": "PA166156992",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          },
          {
            "variant": "rs1142345",
            "gene": "TPMT",
            "drug": "6-mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "rs1142345",
              "Gene": "TPMT",
              "Drug(s)": "6-mercaptopurine",
              "PMID": "35431360",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "In 42 Colombian pediatric ALL patients with complete TPMT typing, rs1142345 T/C heterozygotes (4 patients) showed no statistically significant association with 6-mercaptopurine dose reduction, interruption, neutropenia, liver toxicity, relapse, death, or laboratory markers compared with T/T.",
              "Sentence": "rs1142345 is not associated with increased risk of Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death when treated with 6-mercaptopurine in children with Disease:Acute lymphoblastic leukemia.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver toxicity, Side Effect:Febrile neutropenia, Side Effect:6-mercaptopurine dose reduction, Side Effect:6-mercaptopurine interruption, Side Effect:Toxic death",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "35431360",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "\"Seventy pediatric patients were included in the study. Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.\"",
                "\"[Table 4] summarizes the results of the bivariate analyzes in which the correlation between the genetic variants of the SNPs of interest in NUDT15 and TPMT and the side effects of interest. No association was found between the outcomes of interest and the genetic variant of NUDT15 or any TPMT polymorphisms evaluated individually.\"",
                "\"Data are presented as absolute frequency values for each outcome evaluated. No statistically significant association was found between any of the polymorphisms studied and the outcomes of interest.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1142345",
                "variant_id": "PA166156978",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 0.9333333333333333
              }
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.6127135011884902,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 3,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.5798982942805571,
            "annotation": {
              "Study Parameters ID": 1451769007,
              "Variant Annotation ID": 1451769000,
              "Study Type": "cohort",
              "Study Cases": 68.0,
              "Study Controls": null,
              "Characteristics": "Pediatric ALL",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1451769007,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1451769000,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 68.0,
                "prediction": 68,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Pediatric ALL",
                "prediction": "Colombian pediatric ALL patients in maintenance therapy (BFM ALLIC 2009) genotyped for NUDT15 rs116855232; overall genotype distribution",
                "score": 0.8582710027694702,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.94,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "C/C genotype (NUDT15 rs116855232)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.802",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5798982942805571,
            "annotation": {
              "Study Parameters ID": 1451768400,
              "Variant Annotation ID": 1451768380,
              "Study Type": "cohort",
              "Study Cases": 68.0,
              "Study Controls": null,
              "Characteristics": "Pediatric ALL",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1451768400,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1451768380,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 68.0,
                "prediction": 68,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Pediatric ALL",
                "prediction": "Colombian pediatric ALL patients in maintenance therapy (BFM ALLIC 2009) genotyped for NUDT15 rs116855232; overall genotype distribution",
                "score": 0.8582710027694702,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.06,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "C/T genotype (NUDT15 rs116855232)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.802",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.4620920910554774,
            "annotation": {
              "Study Parameters ID": 1451769045,
              "Variant Annotation ID": 1451769040,
              "Study Type": "cohort",
              "Study Cases": 68.0,
              "Study Controls": null,
              "Characteristics": "Pediatric ALL",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1451769045,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1451769040,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 68.0,
                "prediction": 68,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Pediatric ALL",
                "prediction": "Colombian pediatric ALL patients in maintenance therapy (BFM ALLIC 2009) genotyped for NUDT15 rs116855232; allele frequency comparison with Latin American ALFA data",
                "score": 0.8555655479431152,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.97,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "C allele (NUDT15 rs116855232)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": 0.994,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "C allele (LatinAmerica1 ALFA)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.802",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 1,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 68,
              "Study Controls": null,
              "Characteristics": "Colombian pediatric ALL patients in maintenance therapy (BFM ALLIC 2009) genotyped for NUDT15 rs116855232; allele frequency comparison with Latin American ALFA data",
              "Characteristics Type": "disease",
              "Frequency In Cases": 0.03,
              "Allele Of Frequency In Cases": "T allele (NUDT15 rs116855232)",
              "Frequency In Controls": 0.006,
              "Allele Of Frequency In Controls": "T allele (LatinAmerica1 ALFA)",
              "P Value": "= 0.802",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}